KY 234 is an orally effective inhibitor that targets thromboxane A2 production, with an IC50 of 5 μM. KY 234 significantly inhibits leukotriene D4 (LTD4), histamine, and antigen-induced bronchoconstriction in guinea pigs, with IC50 values of 6.0 mg/kg, 2.5 mg/kg, and 6.3 mg/kg, respectively[1].
[1] KAMIYA S, et al. Thromboxane A2 synthetase inhibitors with histamine H1-blocking activity: synthesis and evaluation of a new series of indole derivatives[J]. Chemical and pharmaceutical bulletin, 1995, 43(10): 1692-1695.